(CercleFinance.com) – bioMérieux is down by more than 2%, penalized by a decline in Berenberg’s recommendation to ‘keep’ to ‘sell’ with a target price of 120 to 110 euros, as the company considers the stock to be the least appreciated in its sector.
The biggest question is what the post-Covid-19 landscape will look like,’ warns the broker, who maintains Qiagen as his ‘first choice’ in the European diagnostics sector, and retains its buy recommendations on IP Group and Biocartis.Copyright (c) 2021 CercleFinance.
What is the trend in the stock market?
Why is the stock market going up right now?
Is this a good time to invest in the stock market?
Why are the stock markets down?
Why the scholarship?
Why is the CAC 40 falling today?
Who works at the stock exchange?
What action for 2021?
Where to invest your money in 2021?
What actions should be included in a PEA 2020?
Which shares to buy in 2020?
How will the stock market evolve in 2020?